Secukinumab for treatment of psoriasis: does secukinumab precipitate or promote the presentation of cutaneous T-cell lymphoma?

Yoo, J; Shah, F; Velangi, S; Stewart, G; Scarisbrick, JS

Yoo, J (reprint author), Univ Hosp Birmingham, Dept Dermatol, Mindelsohn Way, Birmingham B15 2TH, W Midlands, England.

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019; 44 (4): 414

Abstract

Secukinumab is an interleukin (IL)-17 monoclonal antibody inhibiting T-helper (Th)1-mediated immune response. It has proven high efficacy for moderate......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索